BLAINJECTIONINJECTABLE
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Intelligence
6/8 — Comprehensive
KEVZARA (sarilumab) by Sanofi is interleukin 6 receptor antagonists [moa]. First approved in 2017.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Started Apr 2026
300 enrolled
Polymyalgia Rheumatica
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Started Aug 2023
56 enrolled
Lung Cancer
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Started Apr 2020
60 enrolled
COVID-19 Drug Treatment
Sarilumab COVID-19
Started Mar 2020
420 enrolled
Corona Virus Infection
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Started Mar 2020
1,912 enrolled
COVID-19
Worked on KEVZARA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.